Matches in Wikidata for { <http://www.wikidata.org/entity/Q96159029> ?p ?o ?g. }
Showing items 1 to 42 of
42
with 100 items per page.
- Q96159029 description "article scientifique publié en 2020" @default.
- Q96159029 description "artículu científicu espublizáu n'abril de 2020" @default.
- Q96159029 description "scientific article published on 18 April 2020" @default.
- Q96159029 description "wetenschappelijk artikel" @default.
- Q96159029 description "наукова стаття, опублікована 18 квітня 2020" @default.
- Q96159029 name "Analysis of Progression Patterns and Failure Sites of Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Receiving First-line Treatment of Tyrosine Kinase Inhibitors" @default.
- Q96159029 name "Analysis of Progression Patterns and Failure Sites of Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Receiving First-line Treatment of Tyrosine Kinase Inhibitors" @default.
- Q96159029 type Item @default.
- Q96159029 label "Analysis of Progression Patterns and Failure Sites of Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Receiving First-line Treatment of Tyrosine Kinase Inhibitors" @default.
- Q96159029 label "Analysis of Progression Patterns and Failure Sites of Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Receiving First-line Treatment of Tyrosine Kinase Inhibitors" @default.
- Q96159029 prefLabel "Analysis of Progression Patterns and Failure Sites of Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Receiving First-line Treatment of Tyrosine Kinase Inhibitors" @default.
- Q96159029 prefLabel "Analysis of Progression Patterns and Failure Sites of Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Receiving First-line Treatment of Tyrosine Kinase Inhibitors" @default.
- Q96159029 P1433 Q96159029-5B811197-9A60-4D0F-A153-3FAB5960295A @default.
- Q96159029 P1476 Q96159029-00B55831-22E3-45D7-B8AA-8488ADD7FCDA @default.
- Q96159029 P2093 Q96159029-304CDF28-5572-4228-9D51-E8A95960E827 @default.
- Q96159029 P2093 Q96159029-331059D3-8E4D-4617-A91A-0B92891B7C87 @default.
- Q96159029 P2093 Q96159029-93589AE2-DFFB-4EF4-9BDC-4D155F9F72E0 @default.
- Q96159029 P2093 Q96159029-981E0740-5B7C-4648-BBF1-D7965C3BA95E @default.
- Q96159029 P2093 Q96159029-9C8F1F30-75FF-4C0B-92F7-642158DC8621 @default.
- Q96159029 P2093 Q96159029-D6C87716-3D53-48B4-8CDA-2B9E233B26F2 @default.
- Q96159029 P2093 Q96159029-E8909A5A-8EFF-471C-BC69-2616568BFD25 @default.
- Q96159029 P2093 Q96159029-EBEB9178-D0F6-4C6D-BB0B-76400C71783F @default.
- Q96159029 P31 Q96159029-2D255F24-D279-40C1-BD0C-579967D59F1F @default.
- Q96159029 P356 Q96159029-726F5252-37A7-43B7-A6B6-E303896B46E8 @default.
- Q96159029 P577 Q96159029-73A06C7D-23F4-497F-ACF8-D4CCA82228F9 @default.
- Q96159029 P698 Q96159029-920AA81B-1242-4790-A95B-3FAA0AE58771 @default.
- Q96159029 P356 J.CLLC.2020.04.004 @default.
- Q96159029 P698 32505632 @default.
- Q96159029 P1433 Q332299 @default.
- Q96159029 P1476 "Analysis of Progression Patterns and Failure Sites of Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Receiving First-line Treatment of Tyrosine Kinase Inhibitors" @default.
- Q96159029 P2093 "Bo Zhang" @default.
- Q96159029 P2093 "Chen-Chen Zhang" @default.
- Q96159029 P2093 "Hong-Yan Zhang" @default.
- Q96159029 P2093 "Tian-le Shen" @default.
- Q96159029 P2093 "Wen Yu" @default.
- Q96159029 P2093 "Xiao-Long Fu" @default.
- Q96159029 P2093 "Xiao-Yang Li" @default.
- Q96159029 P2093 "Xue-Ru Zhu" @default.
- Q96159029 P31 Q13442814 @default.
- Q96159029 P356 "10.1016/J.CLLC.2020.04.004" @default.
- Q96159029 P577 "2020-04-18T00:00:00Z" @default.
- Q96159029 P698 "32505632" @default.